Abivax (ABVX) Research & Development (2022 - 2026)

Abivax's Research & Development history runs 5 years deep, the most recent figure standing at -$58.0 million for Q1 2026.

• On a quarterly basis, Research & Development fell 40.3% year-over-year to -$58.0 million in Q1 2026; TTM through Mar 2026 was -$218.3 million, a 35.38% decrease from a year earlier, with the FY2025 full-year figure at -$207.0 million, down 30.53% from the prior year.
• Research & Development slipped to -$58.0 million in Q1 2026 per ABVX's latest filing, from -$51.7 million in the prior quarter.
• Across five years, Research & Development topped out at -$49.28 in Q4 2022 and bottomed at -$64.8 million in Q3 2025.
• The 5-year median for Research & Development is -$41.3 million (2025), against an average of -$38.0 million.
• Across the five-year window, Research & Development sank 37113036.64% in 2024 and decreased 6.46% in 2025, its largest moves.
• Year by year, Research & Development stood at -$49.28 in 2022, then tumbled by 125.33% to -$111.04 in 2023, then sank by 37113036.64% to -$41.2 million in 2024, then decreased by 25.52% to -$51.7 million in 2025, then decreased by 12.13% to -$58.0 million in 2026.
• Per Business Quant, the three latest ABVX Research & Development figures stand at -$58.0 million (Q1 2026), -$51.7 million (Q4 2025), and -$64.8 million (Q3 2025).